ReviewNature reviews. Immunology2014
Cytokines in inflammatory bowel disease.
Review in Nature reviews. Immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 1,370 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase I, Open-label, Fast-track Dose-escalation Clinical Trial Exploring the Safety and the Tolerability of Autologous ex Vivo Expanded Regulatory T Cells in Adults With Ulcerative Colitis
Deep Nutritional Phenotyping of Adult Crohn's Disease Patients: a Focus on Protein Intake and Sarcopenia
Efficacy of Different Biological Treatments in Patients With Inflammatory Bowel Disease After One Year of Treatment in Upper Egypt
Who cites it
1,370 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Pooled it
- Emerging CAR-Treg and regulatory T cell therapies for inflammatory bowel diseases: a systematic review of a new era of treatment.Frontiers in immunology · 2026Pooled it
- Exploring exercise modalities and their impact on inflammatory bowel disease: A systematic review of rodent colitis models.World journal of gastroenterology · 2025Pooled it
- Benefit-risk profile of upadacitinib: exploratory post hoc analysis of phase 2b/3 studies in patients with moderately to severely active ulcerative colitis or Crohn's disease.Journal of Crohn's & colitis · 2026Trial
- Evidence for a Modulatory Effect of a 12-Week Pomegranate Juice Intervention on the Transcriptional Response in Inflammatory Bowel Disease Patients Reducing Fecal Calprotectin Levels: Findings From a Proof-of-Principle Study.Molecular nutrition & food research · 2025Trial
- Bowel urgency in ulcerative colitis: effect of baseline urgency and change in urgency in response to mirikizumab.Journal of patient-reported outcomes · 2025Trial
- Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY).Journal of Crohn's & colitis · 2025Trial
- Crosstalk between circRNAs and the classic signaling pathways in IBD.RNA biology · 2026Review
- Modification of the dextran sodium sulfate model to identify agents that induce or exacerbate inflammatory bowel disease.Journal of immunotoxicology · 2026Article
- Transforming growth factor β-activated kinase 1 as a central integrator of immune-microbiota crosstalk in colitis (Review).Experimental and therapeutic medicine · 2026Review
- Ebastine attenuates DSS-induced ulcerative colitis via modulation of NF-κB, oxidative stress and pro-inflammatory cytokines: evidence for antihistamine repurposing.Inflammopharmacology · 2026Article
- A systematic transcriptomic atlas and predictive framework for metabolite-driven T cell state transitions.iScience · 2026Article
- Zbtb44-mediated transcriptional repression critically regulates colonic inflammation.Nature immunology · 2026Article
- A Novel Cationic Antimicrobial Peptide ScymidgutinProbiotics and antimicrobial proteins · 2026Article
- Engineering immune cell therapies for inflammatory bowel disease: from stem cells to CAR T cells.Nature reviews. Gastroenterology & hepatology · 2026Review
- Anti-inflammatory activity of Chlorella polysaccharide AHP.Molecular and cellular biochemistry · 2026Article
- Mechanistic insights into sitagliptin's action in rat inflammatory bowel disease: involvement of the NO-cGMP-KATP pathway.Research in pharmaceutical sciences · 2026Article
- Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.Signal transduction and targeted therapy · 2026Review
- Prevalence, timing and risk factors of extraintestinal manifestations in inflammatory bowel disease: a retrospective cohort study from a German tertiary referral center.Crohn's & colitis 360 · 2026Article
- Heat-InactivatedNutrients · 2026Article
1,310 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cytokines have a crucial role in the pathogenesis of inflammatory bowel diseases (IBDs), such as Crohn's disease and ulcerative colitis, where they control multiple aspects of the inflammatory response. In particular, the imbalance between pro-inflammatory and anti-inflammatory cytokines that occurs in IBD impedes the resolution of inflammation and instead leads to disease perpetuation and tissue destruction. Recent studies suggest the existence of a network of regulatory cytokines that has important implications for disease progression. In this Review, we discuss the role of cytokines produced by innate and adaptive immune cells, as well as their relevance to the future therapy of IBD.
Indexed as
Identifiers
24751956What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.